Advancements and Challenges in Cancer Immunotherapy

Abstract

The immune system plays a major role leading to extraordinary immunotherapeutic interventions. Immune checkpoint blockade has emerged as a revolutionary development in cancer therapeutics. Adoptive cell therapy (ACT) has come out as a promising avenue, involving the infusion of tumor-infiltrating lymphocytes (TIL) or genetically engineered T cells showing innovative T cell receptors (TCR) or chimeric antigen receptors (CAR). These interventions encourage to utilize the capacity of the immune system to target tumor cells successfully. Supportive outcomes have been recorded across various tumor types, resulting in the advancement of global clinical trials to refine and improvise ACT protocols. Significantly favorable results have been seen in hematological malignancies as well as impressive development in the case of ACT against solid tumors have become an important milestone for the researchers. This chapter discusses the different types and advancements in ACT, describes associated toxicities, and predicts its future potential in cancer therapeutics